Navigation Links
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
Date:6/30/2009

Results Demonstrate Positive Proof of Mechanism

SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.

The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species. While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.

"The AM211 clinical PD data confirms what we previously observed in pre-clinical models," said Isabelle DeArmond, M.D., Vice President, Clinical Development. "While a great deal of clinical work remains on this program, we are particularly excited since we believe DP2 antagonism would be a novel therapeutic approach to various respiratory diseases."

Bob Baltera, Chief Executive Officer, added, "Once again the Amira team demonstrates our ability to quickly, efficiently and accurately translate scientific efforts into meaningful therapeutic candidates. The fact that we now have clinical data only 25 months after we initiated scientific efforts on this target in our laboratories is a source of pride for the entire Amira team."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.

    Media Contact
    Ian Stone
    Russo Partners
    Tel: +1 619 528 2220
    ian.stone@russopartnersllc.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
2. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
3. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
4. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
5. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
6. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
7. Amira Pharmaceuticals Appoints First Vice President of Development
8. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
9. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
10. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
11. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Altec ... The Resource Group as their 2016 Microsoft Dynamics Partner of the Year at ... CA. The award recognizes The Resource Group for their outstanding relationship with ...
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year ... are thinking about summer internships , which can be frustrating when they don’t ... at Garden Media Group, a boutique public relations firm outside of Philadelphia, have offered ...
(Date:3/23/2017)... Richey, FL (PRWEB) , ... March 23, 2017 , ... ... announce that 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality ... honors those who have contributed not only to the association, but also to the ...
(Date:3/23/2017)... ... 23, 2017 , ... On 2 March 2017, the United ... Operations Command’s Patriot Award. The award was presented by the USSOCOM Commander, General ... for its significant and enduring support to the command. , Accepting the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 A ... preparation market is expected to reach USD 7.2 billion by ... 7.1%. Sample preparation is a procedure in which a sample ... step in most analytical procedures since the methods are often ... is one of the most shared procedures in the lab. ...
(Date:3/23/2017)... 2017 CENTRO DE IMAGEM DIAGNOSTICOS S.A. (" ... of Law 6,404/76 and Instruction 358/02 of the Brazilian ... and the market in general that it entered yesterday, ... Diagnosticos por Imagem Ltda. (" CDI "), into an ... ASSOCIADOS LTDA. (" Partnership " and " Acquisition "). ...
(Date:3/23/2017)... -- Newborns are highly vulnerable to infections and ... young immune systems typically mount weak antibody responses. ... strong vaccine responses in newborn animals, including monkeys ... — by adding compounds known as adjuvants that ... they also describe improved adjuvant formulations that could ...
Breaking Medicine Technology: